F.L. Putnam Investment Management’s Takeda Pharmaceutical TAK Stock Holding History

F.L. Putnam Investment Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12,683	Closed	-$164K	–	721
2024 Q2	$164K	Sell	12,683 -949	-7%	-$12.6K	﹤0.01%	541
2024 Q1	$189K	Buy	+13,632	New	+$198K	﹤0.01%	474

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

F.L. Putnam Investment Management's TAK Position: Q3 2024 in Review

F.L. Putnam Investment Management sold out of Takeda Pharmaceutical (TAK) in Q3 2024, closing a stake of 12,683 shares — an estimated $164K sold.

F.L. Putnam Investment Management first reported a position in TAK in Q1 2024 and held it in 2 quarters. The position peaked at $189K in Q1 2024. 299 funds tracked by Wall St. Rank hold TAK as of Q3 2024.

F.L. Putnam Investment Management reported no remaining Takeda Pharmaceutical position as of Q3 2024 after selling out during the quarter.
F.L. Putnam Investment Management sold 12,683 Takeda Pharmaceutical shares in Q3 2024, an estimated $164K.
F.L. Putnam Investment Management first reported a position in Takeda Pharmaceutical in Q1 2024 and held it in 2 quarters.
F.L. Putnam Investment Management's Takeda Pharmaceutical position peaked at $189K in Q1 2024.
299 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2024.

Based on F.L. Putnam Investment Management's 13F filing for Q3 2024, filed 8 Nov 2024.